1. Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery
- Author
-
J.C. Park, H. Bernstein, S. Loughhead, R. Zwirtes, J. Jennings, V. Nicolini, C. Klein, L.C. Deak, P. Umana, C. Trumpfheller, and A. Sharei
- Subjects
Cell Squeeze ,therapeutic cancer vaccine ,cell therapy ,MHC class I antigen presentation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Cell Squeeze is a novel technology that relies on temporarily disrupting the cell membrane to deliver cargo directly into the cytosol. This approach is applicable to a broad range of cell types (peripheral blood mononuclear cells, red blood cells, hematopoietic stem cells, etc.) and cargos (peptides, proteins, small molecules, nucleic acids, and gene-editing complexes) while minimally disrupting normal cell function. By enabling direct cytosolic delivery, one can use this technology to dramatically enhance major histocompatibility complex (MHC) class I presentation of antigens (Ags) for CD8+ T-cell activation—a longstanding challenge for the therapeutic cancer vaccine field that has generally relied on cross-presentation of endocytosed Ags. In addition, by coupling improved MHC class I presentation with coexpression of additional stimulatory factors or systemic immune modulators, one can further enhance the potential impact of an antitumor CD8 response. Pursuing a more direct cellular engineering strategy, which is independent of viral transduction, genetic manipulation, and expansion steps, enables
- Published
- 2022
- Full Text
- View/download PDF